Advertisement
Advertisement
CATX
Perspective Therapeutics, Inc.
3.85
USDSponsored
-0.01
-0.26%
May 15, 15:59 UTC -4
Closed
After-Market
3.81
-0.04
-0.91%
CATX Earnings Reports
Positive Surprise Ratio
CATX beat 23 of 35 last estimates.
66%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Perspective Therapeutics, Inc. earnings per share and revenue
On May 11, 2026, CATX reported earnings of -0.25 USD per share (EPS) for Q1 26, beating the estimate of -0.30 USD, resulting in a 17.25% surprise. Revenue reached 76.00 thousand, compared to an expected 139.66 thousand, with a -45.58% difference. The market reacted with a -2.84% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
ProKidney Corp. Class A Ordinary Shares
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+0.57%
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
$0.29
Actual
-$0.04
Surprise
-113.64%
Incannex Healthcare Limited - ADR
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.94
Actual
-$11.22
Surprise
-1088.38%
Marker Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.44%
PLUS THERAPEUTICS, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.89
Actual
-$1.05
Surprise
-16.98%
VYNE Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.08
Surprise
+56.43%
Scienture Holdings, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.08
Surprise
+64.35%
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
FAQ
What were Perspective Therapeutics, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Perspective Therapeutics, Inc. reported EPS of -$0.25, beating estimates by 17.25%, and revenue of $76.00K, -45.58% below expectations.
How did the market react to Perspective Therapeutics, Inc.'s Q1 2026 earnings?
The stock price moved down -2.84%, changed from $3.88 before the earnings release to $3.77 the day after.
When is Perspective Therapeutics, Inc. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Perspective Therapeutics, Inc.'s next earnings report?
Based on --
analysts, Perspective Therapeutics, Inc. is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement